Cargando…

Retreatment of symptomatic hepatitis C virus genotype 3 associated mixed cryoglobulinemia with sofosbuvir and ribavirin: a case report

A 52-year-old woman with chronic hepatitis C virus genotype 3 infection developed clinically symptomatic mixed cryoglobulinemia. She started pegylated interferon and ribavirin therapy and in week 12 became negative for HCV RNA with resolution of clinical signs of cryoglobulinemia. The dual treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zarębska-Michaluk, Dorota, Stępień, Piotr M., Paluch, Katarzyna, Pabjan, Paweł
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000747/ https://www.ncbi.nlm.nih.gov/pubmed/29904727 http://dx.doi.org/10.5114/ceh.2018.75960

Ejemplares similares

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2016)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
por: Pabjan, Paweł, et al.
Publicado: (2022)

Megamitochondria formation in hepatocytes of patient with chronic hepatitis C – a case report
por: Wieczorek, Anna, et al.
Publicado: (2017)

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Severe intrahepatic cholestasis and liver failure after stanozolol usage – case report and review of the literature
por: Stępień, Piotr M., et al.
Publicado: (2015)

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment
por: Ishikawa, Toru, et al.
Publicado: (2018)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
por: Hassan, Amro M, et al.
Publicado: (2018)

Genotype 3-hepatitis C virus’ last line of defense
por: Zarębska-Michaluk, Dorota
Publicado: (2021)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
Publicado: (2019)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
por: Han, Sung Yong, et al.
Publicado: (2021)

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
por: Abdel-Moneim, Adel, et al.
Publicado: (2018)

Mixed cryoglobulinemia
por: Ferri, Clodoveo
Publicado: (2008)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis
por: Liu, Hui, et al.
Publicado: (2016)

Hepatitis C Virus Infection and Mixed Cryoglobulinemia
por: Lauletta, Gianfranco, et al.
Publicado: (2012)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015)

Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis
por: He, Qiu-Feng, et al.
Publicado: (2016)

Safety and Efficacy of Sofosbuvir with Ribavirin® in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience
por: Butt, Nazish, et al.
Publicado: (2019)

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
por: Saadoun, David, et al.
Publicado: (2014)

Viral hepatitis C treatment shortening – what is the limit?
por: Zarębska-Michaluk, Dorota
Publicado: (2019)

Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
por: Yada, Masayoshi, et al.
Publicado: (2018)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
por: Mucenic, Marcos, et al.
Publicado: (2019)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
por: Seo, Hee Yeon, et al.
Publicado: (2020)

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
por: Rosenthal, Philip, et al.
Publicado: (2019)

Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
por: Loo, Jing Hong, et al.
Publicado: (2022)

Symptomatic Mixed Cryoglobulinemia during HIV Primary Infection: A Case Report
por: Genet, Philippe, et al.
Publicado: (2011)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients
por: Smirne, Carlo, et al.
Publicado: (2022)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
por: Yeon, Jong Eun
Publicado: (2018)

Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
por: Liu, Chen-Hua, et al.
Publicado: (2018)

Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
por: Smirne, Carlo, et al.
Publicado: (2021)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
por: Ballester-Ferré, Maria Pilar, et al.
Publicado: (2017)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
por: de Medeiros, Lucas Pereira Jorge, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ggg81qu3b3khdvhvna58183lj2